Today Asymmetrex continues its efforts to bring more attention to the long-standing need for tissue stem cell counting in regenerative medicine. In a post on RegMedNet, the company contrasts the quantitative dosing precision required for pharmaceutical drug trials to the complete vacuum of quantitative dosing for tissue stem cells in regenerative medicine trials. Asymmetrex invites regenerative medicine companies and physicians’ trials group to evaluate the company’s new AlphaSTEM technology for counting tissue stem cells. Asymmetrex predicts that adoption of the technology in 2016 would have a major impact on the quality of stem cell medicine clinical trials.
Related Posts
Recent Posts
- Asymmetrex®’s Kinetic Stem Cell (KSC) Counting Technology is Featured in the Parent’s Guide to Cord Blood Foundation® June Newsletter
- Asymmetrex® Presents New Developments in its Rapid Stem Cell Counting Technology at the ARMI|BioFabUSA Meeting in the Millyard on Regenerative Medicine Biomanufacturing
- Asymmetrex® CEO Publishes New Book on Missing Elements of U.S. COVID Science
- Asymmetrex Issued U.S. Trademark Registration for Business Name
- Asymmetrex Discusses Stem Cell-Specific Dosing in Veterinary Medicine with Tech Company News
Tags
- Adult Stem Cells
- Announcements
- Asymmetrex News
- Biotechnology
- Immortality and Stem Cells
- Industry News
- Interview
- Kinetic Stem Cell Counting
- Online Workshop
- Regenerative Medicine
- Reports
- Stem Cell Counting
- Stem Cell Information
- Stem Cell Injections
- Stem Cell Medicine
- Stem Cell Research
- Stem Cell Technology
- Stem Cell Toxicology
- Webinar
Leave a Reply